Filing Flows › Health Care › Macrogenics (MGNX)
Macrogenics (MGNX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Macrogenics (MGNX) Q2 2026 earnings results →
Q2 2026 Revenue up 378% year over year to $32.8M · 59¢ of every $1 of revenue kept as net profit · operating margin -42.2%
Macrogenics made $32.8M in Q2 2026 (+378% Y/Y): Collaborative and other agreements $25.5M, Royalty revenue $7.3M. Operating margin -42.2%, net earnings $19.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $32.8M in Q2 2026, up 378% year over year and up 58% from the previous quarter. Collaborative and other agreements was the largest line at 78% of revenue. Collaborative and other agreements added $19.9M year over year (up 359%), 77% of the total change.
Operating costs exceeded revenue by $13.9M, an operating margin of -42.2%. Total costs fell 7% while revenue rose 378%. Net earnings were $19.5M. The effective tax rate was 0.0%. Non-operating items added $33.4M, 171% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$40.7M. Non-cash charges added back $708K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $62.9M. Capital expenditures of $806K exceeded it, leaving free cash flow of −$41.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $32.8M | +378% | -42.2% | $19.5M | −$40.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $20.8M | +58% | -161.0% | −$36.8M | −$35.8M |
| Q4 2025 | 10-K | Mar 9, 2026 | $41.2M | +113% | -29.3% | −$14.2M | $43.0M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $72.8M | -34% | 25.6% | $16.8M | −$30.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $22.2M | +106% | -165.3% | −$36.3M | −$47.0M |
| Q1 2025 | 10-Q | May 13, 2025 | $13.2M | +45% | -323.1% | −$41.0M | −$46.9M |
| Q4 2024 | 10-K | Mar 20, 2025 | $19.4M | +80% | -273.0% | −$15.4M | −$38.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Sanofi S.A. (Sanofi) — 33% of its revenue · Stated in 10-K (XBRL) · source
- Incyte Corporation (Incyte) — 32% of its revenue · Stated in 10-K (XBRL) · source
- Gilead Sciences, Inc (Gilead) — 24% of its revenue · Stated in 10-K (XBRL) · source
About Macrogenics
Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. “MacroGenics ® , the MacroGenics logo, DART ® , TRIDENT ® and the phrases Breakthrough Biologics, Life-Changing Medicines ® and Developing Breakthrough Biologics, Life-Changing Medicines ® are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.
In its own words, from its 10-K, filed Mar 9, 2026.
Macrogenics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +378% against the peers' median +10%. Operating margin: -42.2% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MGNX Macrogenics | Q2 2026 | $32.8M | +378% | -42.2% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Macrogenics 10-Q on SEC EDGAR · CIK 1125345 · Pharmaceutical Preparations
13F: who owns MGNX and who is buying
More on MGNX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results